Literature DB >> 27255578

Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing.

Calogero Cammà1, Giuseppe Cabibbo2, Antonio Craxì2.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27255578     DOI： 10.1016/j.jhep.2016.04.033

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  16 in total

1.  Direct acting antiviral agents and hepatocellular carcinoma development: don't take it for granted.

Authors:  Antonio Riccardo Buonomo; Ivan Gentile; Guglielmo Borgia
Journal:  Transl Gastroenterol Hepatol       Date:  2017-12-06

2.  Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk.

Authors:  Marcus-Alexander Wörns; Peter Robert Galle; Stefan Zeuzem; Peter Schirmacher; Michael Manns; Arndt Vogel
Journal:  Dtsch Arztebl Int       Date:  2017-09-04       Impact factor: 5.594

Review 3.  Remaining clinical issues in hepatitis C treatment.

Authors:  Alexander Wong; Cynthia Tsien; Sarah Mansour; Curtis Cooper
Journal:  Can Liver J       Date:  2018-07-17

4.  Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.

Authors:  Annsa C Huang; Neil Mehta; Jennifer L Dodge; Francis Y Yao; Norah A Terrault
Journal:  Hepatology       Date:  2018-05-16       Impact factor: 17.425

Review 5.  Epidemiology and Management of Hepatocellular Carcinoma.

Authors:  Laura Kulik; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2018-10-24       Impact factor: 22.682

6.  Direct-Acting Antiviral Agents Reduce the Risk of Malignant Transformation of Hepatobiliary Phase-Hypointense Nodule without Arterial Phase Hyperenhancement to Hepatocellular Carcinoma on Gd-EOB-DPTA-Enhanced Imaging in the Hepatitis C Virus-Infected Liver.

Authors:  Yoshiaki Shimizu; Kuniaki Arai; Taro Yamashita; Tatsuya Yamashita; Tetsuro Shimakami; Kazunori Kawaguchi; Kazuya Kitamura; Yoshio Sakai; Eishiro Mizukoshi; Masao Honda; Azusa Kitao; Kazuto Kozaka; Satoshi Kobayashi; Shuichi Kaneko
Journal:  Liver Cancer       Date:  2020-01-07       Impact factor: 11.740

7.  The Risk of Hepatocellular Carcinoma After Directly Acting Antivirals for Hepatitis C Virus Treatment in Liver Transplanted Patients: Is It Real?

Authors:  Alessio Strazzulla; Rosa Maria Rita Iemmolo; Ennio Carbone; Maria Concetta Postorino; Maria Mazzitelli; Mario De Santis; Fabrizio Di Benedetto; Costanza Maria Cristiani; Chiara Costa; Vincenzo Pisani; Carlo Torti
Journal:  Hepat Mon       Date:  2016-10-30       Impact factor: 0.660

Review 8.  Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon?

Authors:  Amna Subhan Butt; Fatima Sharif; Shahab Abid
Journal:  World J Hepatol       Date:  2018-02-27

9.  Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance.

Authors:  Anna S Griffith; Paul H Hayashi; Lauren Mb Burke; Autumn J McRee
Journal:  J Hepatocell Carcinoma       Date:  2018-05-31

10.  Dynamic Changes of the Frequency of Classic and Inflammatory Monocytes Subsets and Natural Killer Cells in Chronic Hepatitis C Patients Treated by Direct-Acting Antiviral Agents.

Authors:  Gang Ning; Yi-Ting Li; You-Ming Chen; Ying Zhang; Ying-Fu Zeng; Chao-Shuang Lin
Journal:  Can J Gastroenterol Hepatol       Date:  2017-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.